AstraZeneca Strengthens Diabetes R&D With Option On Astellas/Prosidion's Early-Stage Compounds
This article was originally published in PharmAsia News
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
You may also be interested in...
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff